

PharmaMar presents at MaNaPro & ECMNP its latest advances in the development of compounds of marine origin

- Seven posters of new cancer treatment compounds, forming the basis of the future pipeline, are presented at the International Symposium on Marine Natural Products.
- Three new compounds identified and isolated with *in-vitro* antitumor activity.
- A new process for the isolation of marine bacteria, accelerating the identification of new antitumor compounds.
- Advances continue in the area of Antibody-Drug Conjugates (ADC) with the development of new payloads.
- Chemical synthesis and antitumor activity of PM14 in breast tumors, sarcoma and gastric cancer are shown in preclinical studies.

Peniche (Portugal), September 2nd, 2019.- PharmaMar (MSE:PHM) presents its latest advances in the development of its marine-derived compounds with antitumor activity at the XVI International Symposium on Marine Natural Products (MaNaPro) and the XI European Conference on Marine Natural Products (ECMNP). The meeting is taking place in Peniche, Portugal, from 1st to 5th September 2019.

Compounds with in-vitro antitumor activity

During the Symposium, PharmaMar presents three posters describing the discovery of three new families of compounds that have shown *in-vitro* antitumor activity and that will be evaluated in animal models.

New process for isolating marine bacteria

During the conference, the Company's R&D team will also present a poster on the DTE (dilution-to-extinction) process. This technique allows optimizing the isolation process of marine bacteria, producing new antitumor compounds, thus reducing the production costs of new compounds.

Area of Antibody-Drug Conjugates (ADCs)

PharmaMar will present two posters with two new ADCs: MI180021 and MI130110. ADCs are innovative, next-generation immunotherapeutic agents. ADCs consist of an antibody that identifies and targets antigens on the surface of certain tumor cells, a



molecule (payload) with antitumor activity, and a connector that binds them together.

This research has already led to the licensing of the first family of active molecules to Seattle Genetics, world leader in ADCs, for which PharmaMar received an initial payment of \$5 million in February 2018.

PM14

Finally, a poster on its latest compound in clinical development, PM14, will also be presented. This poster shows the chemical synthesis and activity of the compound in breast, sarcoma and gastric tumors in pre-clinical studies. PM14 began Phase I, with the primary objective of identifying the recommended dose in patients with solid tumors. The secondary objectives of this initial clinical trial are to evaluate the safety profile and to evaluate the pharmacokinetics and pharmacogenomics of the compound.

Posters presented by PharmaMar:

- Isolation of serrawettin analogs from a marine bacteria *Vibrio harveyi*
- New peptides isolated from the Indonesian sponge *Theonella sp.*
- Isolation of minutissamide derivatives from a marine cyanobacteria collected in Pulau
- Isolation of pederin analogue producing bacteria through a dilution-to-extinction based screening platform
- MI180021, a novel ADC with a new marine DNA binder payload, shows outstanding activity against HER2 expressing tumors
- MI130110, a new ADC combining an anti-CD13 antibody and a payload of marine origin shows remarkable *in-vivo* activity
- PM14: a new antitumor compound in clinical studies in patients

"The sea covers three quarters of our planet's surface and is home to about 80% of all living things. In the sea we can find the greatest source of organisms that enable us to develop new drugs to fight all types of diseases", says **José María Fernández, PhD**, President of PharmaMar.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.com
Phone: +34 914444500



Or please visit our website at www.pharmamar.com